SCQOLIT-SF: A revised outcome measure for assessing patient-reported outcomes in non-melanoma skin cancers.

Basal and squamous cell carcinomas (BCCs and SCCs, respectively) pose significant burden for patients and health services. Measuring the quality of life in this cohort is crucial because the management of these cancers may cause significant morbidity despite the low overall mortality. The Skin Cancer Quality Of Life Impact Tool (SCQOLIT), a 10-item patient-reported outcome measure, is widely used for quality-of-life assessment but it has not been validated using factor analysis or Rasch Measurement Theory (RMT).

User and Developer Views on Using AI Technologies to Facilitate the Early Detection of Skin Cancers in Primary Care Settings: Qualitative Semistructured Interview Study.

Background: Skin cancers, including melanoma and keratinocyte cancers, are among the most common cancers worldwide, and their incidence is rising in most populations. Earlier detection of skin cancer leads to better outcomes for patients. Artificial intelligence (AI) technologies have been applied to skin cancer diagnosis, but many technologies lack clinical evidence and/or the appropriate regulatory approvals.

Trends in cutaneous melanoma mortality and incidence in European Union 15+ countries between 1990 and 2019.

Background: Cutaneous melanoma (CM) is the leading cause of skin cancer mortality with associated high healthcare costs. Up-to-date reporting of epidemiological trends for CM is required to project future trends, assess the burden of disease and aid evaluation of new diagnostic, therapeutic and preventative strategies.

Objectives: To describe the trends in CM mortality, incidence, mortality-to-incidence indices (MIIs) and disability-adjusted life years (DALYs) over the last three decades.